Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis-Reference-Cited by-同舟云学术

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

Published:2022-03 Issue:3 Volume:36 Page:283-300
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Yu Huixin,Graham Gordon,David Olivier J.,Kahn Joseph M.,Savelieva Marina,Pigeolet Etienne,Das Gupta Ayan,Pingili Ratnakar,Willi Roman,Ramanathan Krishnan,Kieseier Bernd C.,Häring Dieter A.,Bagger Morten,Soelberg Sørensen Per

Funder

novartis pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-021-00895-w.pdf

Reference27 articles.

1. Milo R. Therapies for multiple sclerosis targeting B cells. Croat Med J. 2019;60(2):87–98.

2. Häusser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol. 2019;10:201.

3. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696–707.

4. Wanleenuwat P, Iwanowski P. Role of B cells and antibodies in multiple sclerosis. Mult Scler Relat Disord. 2019;36:101416.

5. Sabatino JJ Jr, Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9(2): a032037.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ofatumumab in der Behandlung der Multiplen Sklerose – Eine Übersicht der präklinischen und klinischen Daten;Fortschritte der Neurologie · Psychiatrie;2024-08-19

2. Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: A multi‐centre cohort study;Journal of the European Academy of Dermatology and Venereology;2024-07-12

3. Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics;Sclerosis;2024-06-27

4. Extended interval dosing with ocrelizumab in multiple sclerosis;Multiple Sclerosis Journal;2024-04-22

5. Ofatumumab in clinical practice;Neurologie pro praxi;2024-03-06